A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

Study acronym: AMPLIFY-1
StatusNot Yet Recruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Eli Lilly
363 trials monitored
See 16 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity. Participation in the study will last about 2 years.
Trial Details
NCT Number NCT07881432
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Obesity
Related terms Obesity
Enrollment 2,115 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov